cancer-immunotherapy

Documents about cancer-immunotherapy

• Tailoring innovative silver nanoparticles for modern medicine: the importance of size and shape control and functional modifications#318949HAL (France)
• A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA#417546ClinicalTrials.gov
• A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden#454027ClinicalTrials.gov
• Development and evaluation of methodologies for analysis of CTC and ctDNA in patients with ovarian carcinoma#459134Research Online
• The extent of lymph node dissection in early-stage non-small cell lung cancer: current controversies, evidence gaps, and future directions in the immunotherapy era-a narrative review.#685614NCBI PubMed Central
• Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas#801057ClinicalTrials.gov
• Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)#159268HAL (France)
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy#332763ClinicalTrials.gov
• Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective Study#142949Unpaywall
• Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias#143553ClinicalTrials.gov
• CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma#181787ClinicalTrials.gov
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN#125822ClinicalTrials.gov
• Deciphering the Renal tumOr microenvironment to PersonaLize immunE-targeted Treatment (DROPLET): transcriptomic profiling of primary and secondary lesions identified a potential crosstalk between MARCO+ macrophages and deregulated cancer-cell proliferation in mediating progression and therapy response of advanced renal cell carcinoта.#823162IRIS
• Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer#349958ClinicalTrials.gov
• Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629#126710HAL (France)
• Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy#249605ClinicalTrials.gov
• ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)#279487ClinicalTrials.gov
• Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States#475599Figshare
• Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC#811484ClinicalTrials.gov
• Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma#841955ClinicalTrials.gov
• A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies#852554ClinicalTrials.gov
• Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy#869246ClinicalTrials.gov
• Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer#256890ClinicalTrials.gov
• Table 3_Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.xlsx#325703Figshare
• Table 2_Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.xlsx#325704Figshare
• Table 4_Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.xlsx#325705Figshare
• Engineering Nonpathogenic Bacteria for Synergistic Tumor-Targeted Protein Degradation and Immunotherapy by Checkpoint-Inhibiting Nanobodies#440509Figshare
• Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunotherapy in Hepatocellular Carcinoma#841228ClinicalTrials.gov
• Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)#208463ClinicalTrials.gov
• Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma#387157ClinicalTrials.gov
• Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study#474747ClinicalTrials.gov
• Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study#431806S-Space: Seoul National University
• Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials#683949eScholarship
• A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer#154693ClinicalTrials.gov
• Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant#226271ClinicalTrials.gov
• Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.#249611ClinicalTrials.gov
• Data Sheet 1_Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.pdf#325702Figshare
• A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI#424183ClinicalTrials.gov
• Pembrolizumab-based systemic therapy associated with opportunities for subsequent local treatment in advanced or recurrent neuroendocrine carcinoma of the cervix: a five-case series#477036OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer#834143ClinicalTrials.gov
• Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer#481753ClinicalTrials.gov
• Gut Microbiota (GM) Biodiversity in Patients With Solid Tumors Treated With Immune Checkpoint Inhibitors (ICIs): a Monocenter Prospective Study to Identify the Interactions Between GM and ICIs#307436ClinicalTrials.gov
• Predictive value of baseline eosinophil counts for immune-related adverse events in metastatic NSCLC treated with immune checkpoint inhibitors#386527ARPHA OAI-PMH Endpoint
• Programmed cell death-1: from a T-cell immune checkpoint to a regulator of Natural Killer cell biology#677814IRIS
• Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC#846201ClinicalTrials.gov
• Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer#234434ClinicalTrials.gov
• Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma#127607ClinicalTrials.gov
• Significance of GSH and H<sub>2</sub>S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health#273458Europe PMC
• A fully human IgG1 antibody targeting MICA α1 domain inhibits interaction with NKG2D and activates immune effector functions against MICA-expressing cells#276432Repositorio de datos de investigación de la Universidad de Chile Dataverse OAI Archive
• Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer#429747ClinicalTrials.gov